Delora Denney, MD
Family Medicine · Picayune, MSNPI 1881696862
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by AbbVie at 45.3% of the total. Reporting peaked in 2021 at $10,195 and has fallen 92.7% since, to $749 in 2025. Among family medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $124.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Teva Pharmaceuticals USA, Inc.$4K
- Astellas Pharma US Inc$4K
- AstraZeneca$2K
- Amgen$1K
- Lilly USA, LLC$702
- plus $1K from 14 others
What the payments were for
- Consulting fees$2,43510%
- Speaking & faculty fees$12,92054%
- Travel & lodging$1,4436%
- Food & beverage$7,18130%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $10,885 |
| Teva Pharmaceuticals USA, Inc. | 15 | $4,013 |
| Astellas Pharma US Inc | 3 | $3,816 |
| AstraZeneca | 28 | $2,007 |
| Amgen | 23 | $1,169 |
| Lilly USA, LLC | 15 | $702 |
| Pfizer | 9 | $284 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $201 |
| Novo Nordisk | 3 | $191 |
| Astellas Pharma Global Development | 6 | $134 |
| Bayer | 2 | $127 |
| Novartis | 7 | $124 |
| Lundbeck LLC | 2 | $121 |
| Biohaven Pharmaceuticals, Inc. | 3 | $94 |
| GSK | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $33 |
| Edwards Lifesciences | 1 | $30 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,018 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $60,481 |
| MounjaroTirzepatide | 51 | $60,404 |
| JardianceEmpagliflozin | 36 | $52,342 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $36,722 |
| TrulicityDulaglutide | 11 | $21,554 |
| FarxigaDapagliflozin Propanediol | 12 | $19,116 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $17,274 |
| LinzessLinaclotide | 11 | $12,798 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $8,204 |
| SynthroidLevothyroxine Sodium | 34 | $4,095 |
| Ipratropium Bromide | 41 | $3,081 |
| Estradiol | 22 | $2,758 |
| Rosuvastatin Calcium | 254 | $2,386 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 100 | $1,467 |
| Nebivolol Hcl | 40 | $1,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $702 | $81,95862 claims |
| Novo NordiskOzempic | $191 | $60,48145 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,007 | $44,59443 claims |
| GSKTrelegy Ellipta | $37 | $36,72228 claims |
| AbbVieLinzess, Synthroid | $10,885 | $16,89345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Picayune
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Dava ClevelandJackson$100K
- Andrea PhillipsJackson$96K
- Kristi TrimmRidgeland$34K
- Tana CooperBiloxi$25K
- Randall HulingOlive Branch$23K
- Timothy QuinnRidgeland$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.